四价人乳头瘤病毒疫苗在男性中的效力、免疫原性与安全性:一项随机安慰剂对照3期试验的开放标签长期扩展研究结果
本研究为国际多中心随机双盲安慰剂对照3期试验的开放标签长期扩展研究,评估四价HPV疫苗在16-26岁男性中的长期保护效果。早期接种组随访中位9.5年,与基础研究安慰剂组相比,HPV6/11相关外生殖器疣和HPV6/11/16/18相关外生殖器病变发生率均为0.0例/万人年;补种组接种后无新发相关病变。未报告疫苗相关严重不良事件,结果支持男性接种四价HPV疫苗及补种。
要点
- 早期接种组随访中位9.5年,HPV6/11相关外生殖器疣发生率为0.0/万人年,基础研究安慰剂组为137.3/万人年。
- 早期接种组HPV6/11/16/18相关外生殖器病变发生率为0.0/万人年,基础研究安慰剂组为140.4/万人年。
- 补种组接种后无新发HPV6/11相关外生殖器疣和HPV6/11/16/18相关外生殖器病变,未报告疫苗相关严重不良事件。
核心结论
- 四价HPV疫苗对HPV6、11、16、18相关肛门生殖器疾病提供持久保护,结果支持男性接种四价HPV疫苗包括补种。
研究设计与样本
- 基础研究为国际多中心双盲随机安慰剂对照3期试验,在18个国家71个中心纳入16-23岁异性恋男性和16-26岁男男性行为者(MSM),随机1:1接受三剂四价HPV疫苗或安慰剂(第1天、第2月、第6月,0.5mL三角肌注射)。
- 长期扩展研究为7年开放标签随访,在16个国家46个中心纳入基础研究中至少接种一剂四价HPV疫苗者(早期接种组)或基础研究安慰剂组中补种至少一剂四价HPV疫苗者(补种组)。
- 主要效力终点为所有参与者中HPV6/11相关外生殖器疣和HPV6/11/16/18相关外生殖器病变发生率,以及MSM中HPV6/11/16/18相关肛门上皮内瘤变或肛门癌发生率。
- 早期接种组效力分析采用符合方案人群,补种组采用改良意向治疗人群,安全性分析纳入所有随机且至少接种一剂者。
- 2010年8月10日至2017年4月3日长期随访研究共入组1803人,早期接种组936人(异性恋男性827人、MSM 109人),补种组867人(异性恋男性739人、MSM 128人)。
主要发现
- 早期接种组接种第三剂后随访中位9.5年(范围0.1-11.5),补种组接种第三剂后随访中位4.7年(范围0.0-6.6)。
- 长期随访早期接种组与基础研究安慰剂组相比,HPV6/11相关外生殖器疣发生率为0.0/万人年(95%CI 0.0-8.7)vs 137.3/万人年(95%CI 83.9-212.1)。
- 长期随访早期接种组与基础研究安慰剂组相比,HPV6/11/16/18相关外生殖器病变发生率为0.0/万人年(95%CI 0.0-7.7)vs 140.4/万人年(95%CI 89.0-210.7)。
- MSM中HPV6/11/16/18相关肛门上皮内瘤变或肛门癌发生率,早期接种组长期随访为20.5/万人年(95%CI 0.5-114.4),基础研究安慰剂组为906.2/万人年(95%CI 553.5-1399.5)。
- 补种组基础研究期间(接种前)与长期随访期间相比,HPV6/11相关外生殖器疣发生率为149.6/万人年(95%CI 101.6-212.3)vs 0/万人年(95%CI 0.0-13.5),HPV6/11/16/18相关外生殖器病变为155.1/万人年(95%CI 108.0-215.7)vs 0/万人年(95%CI 0.0-10.2),HPV6/11/16/18相关肛门上皮内瘤变或肛门癌为886.0/万人年(95%CI 583.9-1289.1)vs 101.3/万人年(95%CI 32.9-236.3)。
临床怎么用
- 作者认为四价HPV疫苗对HPV6、11、16、18相关肛门生殖器疾病提供持久保护,结果支持男性接种四价HPV疫苗包括补种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The quadrivalent human papillomavirus (HPV) vaccine was shown to prevent infections and lesions related to HPV6, 11, 16, and 18 in a randomised, placebo-controlled study in men aged 16-26 years. We assessed the incidences of external genital warts related to HPV6 or 11, and external genital lesions and anal dysplasia related to HPV6, 11, 16, or 18, over 10 years of follow-up. METHODS: The 3-year base study was an international, multicentre, double-blind, randomised, placebo-controlled trial done at 71 sites in 18 countries. Eligible participants were heterosexual men (aged 16-23 years) or men who have sex with men (MSM; aged 16-26 years). Men who had clinically detectable anogenital warts or genital lesions at screening that were suggestive of infection with non-HPV sexually transmitted diseases, or who had a history of such findings, were excluded. Eligible participants were randomly assigned (1:1) to receive three doses of either quadrivalent HPV vaccine or placebo on day 1, month 2, and month 6, administered as a 0·5-mL injection into the deltoid muscle. The 7-year, open-label, long-term follow-up extension study was done at 46 centres in 16 countries. Participants who received one or more doses of the quadrivalent HPV vaccine in the base study were eligible for enrolment into the long-term follow-up study (early vaccination group). Placebo recipients were offered the three-dose quadrivalent HPV vaccine at the end of the base study; those who received one or more quadrivalent HPV vaccine doses were eligible for enrolment into the long-term follow-up study (catch-up vaccination group). The primary efficacy endpoints were the incidence of external genital warts related to HPV6 or 11 and the incidence of external genital lesions related to HPV6, 11, 16, or 18 in all participants and the incidence of anal intraepithelial neoplasia (including anal warts and flat lesions) or anal cancer related to HPV6, 11, 16, or 18 in MSM only. The primary efficacy analysis was done in the per-protocol population for the early vaccination group, which included participants who received all three vaccine doses, were seronegative at day 1 and PCR-negative from day 1 through month 7 of the base study for the HPV type being analysed, had no protocol violations that could affect evaluation of vaccine efficacy, and had attended at least one visit during the long-term follow-up study. For the catch-up vaccination group, efficacy was assessed in the modified intention-to-treat population, which included participants who had received at least one vaccine dose, were seronegative and PCR-negative for HPV types analysed from day 1 of the base study to the final follow-up visit before receiving the quadrivalent HPV vaccine, and had at least one long-term follow-up visit. Safety was assessed in all randomised participants who received at least one vaccine dose. This study is registered with ClinicalTrials.gov, NCT00090285. FINDINGS: Between Aug 10, 2010, and April 3, 2017, 1803 participants were enrolled in the long-term follow-up study, of whom 936 (827 heterosexual men and 109 MSM) were included in the early vaccination group and 867 (739 heterosexual men and 128 MSM) were included in the catch-up vaccination group. Participants in the early vaccination group were followed up for a median of 9·5 years (range 0·1-11·5) after receiving the third dose of the quadrivalent HPV vaccine, and participants in the catch-up vaccination group were followed up for a median of 4·7 years (0·0-6·6) after receiving the third dose. In early vaccine group participants during long-term follow-up compared with the placebo group in the base study, the incidence per 10 000 person-years of external genital warts related to HPV6 or 11 was 0·0 (95% CI 0·0-8·7) versus 137·3 (83·9-212·1), of external genital lesions related to HPV6, 11, 16, or 18 was 0·0 (0·0-7·7) versus 140·4 (89·0-210·7), and of anal intraepithelial neoplasia or anal cancer related to HPV6, 11, 16, or 18 in MSM only was 20·5 (0·5-114·4) versus 906·2 (553·5-1399·5). Compared with during the base study (ie, before quadrivalent HPV vaccine administration), during the long-term follow-up period, participants in the catch-up vaccination group had no new reported cases of external genital warts related to HPV6 or 11 (149·6 cases per 10 000 person-years [95% CI 101·6-212·3] vs 0 cases per 10 000 person-years [0·0-13·5]) or external genital lesions related to HPV6, 11, 16, or 18 (155·1 cases per 10 000 person-years [108·0-215·7] vs 0 cases per 10 000 person-years [0·0-10·2]), and a lower incidence of anal intraepithelial neoplasia or anal cancer related to HPV6, 11, 16, or 18 (886·0 cases per 10 000 person-years [583·9-1289·1] vs 101·3 cases per 10 000 person-years [32·9-236·3]). No vaccine-related serious adverse events were reported. INTERPRETATION: The quadrivalent HPV vaccine provides durable protection against anogenital disease related to HPV6, 11, 16, and 18. The results support quadrivalent HPV vaccination in men, including catch-up vaccination. FUNDING: Merck Sharp & Dohme.
引用
- Goldstone SE, Giuliano AR, Palefsky JM, et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2021. PMID: 34780705. doi:10.1016/S1473-3099(21)00327-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。